These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 3973803)

  • 1. Development of haloperidol in oil injection formulations.
    Radd BL; Newman AC; Fegely BJ; Chrzanowski FA; Lichten JL; Walkling WD
    J Parenter Sci Technol; 1985; 39(1):48-51. PubMed ID: 3973803
    [No Abstract]   [Full Text] [Related]  

  • 2. Intramuscular haloperidol decanoate for neuroleptic maintenance therapy.
    arap Mengech HN; Wazome EG
    East Afr Med J; 1984 Jun; 61(6):435-8. PubMed ID: 6152736
    [No Abstract]   [Full Text] [Related]  

  • 3. Local muscle damage and oily vehicles: a study on local reactions in rabbits after intramuscular injection of neuroleptic drugs in aqueous or oily vehicles.
    Svendsen O
    Acta Pharmacol Toxicol (Copenh); 1983 Apr; 52(4):298-304. PubMed ID: 6135293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed onset of oculogyric crisis and torticollis with intramuscular haloperidol.
    Jhee SS; Zarotsky V; Mohaupt SM; Yones CL; Sims SJ
    Ann Pharmacother; 2003 Oct; 37(10):1434-7. PubMed ID: 14519055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limonene GP1/PG organogel as a vehicle in transdermal delivery of haloperidol.
    Lim PF; Liu XY; Kang L; Ho PC; Chan YW; Chan SY
    Int J Pharm; 2006 Mar; 311(1-2):157-64. PubMed ID: 16451823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haloperidol decanoate: injection site reactions.
    Maharaj K; Guttmacher LB; Moeller R
    J Clin Psychiatry; 1995 Apr; 56(4):172-3. PubMed ID: 7713859
    [No Abstract]   [Full Text] [Related]  

  • 7. Intramuscular haloperidol or lorazepam and QT intervals in schizophrenia.
    Harvey AT; Flockhart D; Gorski JC; Greenblatt DJ; Burke M; Werder S; Preskorn SH
    J Clin Pharmacol; 2004 Oct; 44(10):1173-84. PubMed ID: 15342619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Apropos of 2 cases of arterial embolism following an injection of oily compounds].
    Vittori F; D'Hotman de Villiers M
    Lyon Med; 1971 Feb; 225(4):305-8. PubMed ID: 5088594
    [No Abstract]   [Full Text] [Related]  

  • 9. Intramuscular absorption and biodistribution of dexamethasone from non-aqueous emulsions in the rat.
    Suitthimeathegorn O; Turton JA; Mizuuchi H; Florence AT
    Int J Pharm; 2007 Mar; 331(2):204-10. PubMed ID: 17250983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of haloperidol as a long-acting neuroleptic in game capture operations.
    Hofmeyr JM
    J S Afr Vet Assoc; 1981 Dec; 52(4):273-82. PubMed ID: 6122740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioavailability of intramuscular versus oral haloperidol in schizophrenic patients.
    Schaffer CB; Shahid A; Javaid JI; Dysken MW; Davis JM
    J Clin Psychopharmacol; 1982 Aug; 2(4):274-7. PubMed ID: 7119135
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of Gilles de la Tourette syndrome with depot neuroleptics.
    Paolucci S; Buttinelli C; Fiume S; Ciani S; Lenzi GL
    Acta Neurol (Napoli); 1984 Jun; 6(3):222-4. PubMed ID: 6591768
    [No Abstract]   [Full Text] [Related]  

  • 13. Microscopic evidence of lymphogenic absorption of oil in humans receiving neuroleptic oily depot preparations intramuscularly.
    Svendsen O; Dencker SJ; Fog R; Gravem AO; Kristjansen P
    Acta Pharmacol Toxicol (Copenh); 1980 Aug; 47(2):157-8. PubMed ID: 6108046
    [No Abstract]   [Full Text] [Related]  

  • 14. Longterm maintenance therapy with depot haloperidol in schizophrenia.
    Zbytovský J
    Homeost Health Dis; 1991; 33(5-6):287. PubMed ID: 18265499
    [No Abstract]   [Full Text] [Related]  

  • 15. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
    Roose K
    Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conventional versus novel conditions for the in vitro dissolution testing of parenteral slow release formulations: application to doxepin parenteral dosage forms.
    Gido C; Langguth P; Kreuter J; Winter G; Woog H; Mutschler E
    Pharmazie; 1993 Oct; 48(10):764-9. PubMed ID: 8265710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Droperidol vs. haloperidol in the initial management of acutely agitated patients.
    Resnick M; Burton BT
    J Clin Psychiatry; 1984 Jul; 45(7):298-9. PubMed ID: 6376480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation.
    Chouinard G; Safadi G; Beauclair L
    J Clin Psychopharmacol; 1994 Dec; 14(6):377-84. PubMed ID: 7884017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation on the photostability of tretinoin in creams.
    Brisaert M; Plaizier-Vercammen JA
    Int J Pharm; 2007 Apr; 334(1-2):56-61. PubMed ID: 17118589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.